Graft failure, which comprises the two clinical entities of primary graft failure and graft rejection, is a serious complication after allogeneic SCT (allo-SCT). Primary graft failure is the inability to sustain donor cell engraftment, and graft rejection is the substantial diminution of donor cells after successful engraftment. 1 Hemophagocytic syndrome (HPS) is a rare complication after allo-SCT, and may lead to poor graft function or graft rejection. The prognosis of patients who developed HPS is extremely poor. [2] [3] [4] [5] Underlying causes of HPS after allo-SCT include viral infection by mainly CMV or EBV, acute GVHD or other immunological mechanisms.
Over the past several years, umbilical cord blood transplantation (CBT) has been increasingly performed for the treatment of adult hematological malignancies because of its availability and the recipient's tolerance of HLA disparity between donor and recipient. 6, 7 It is especially performed in patients who do not have suitable donors and need to undergo allo-SCT as soon as possible. In CBT recipients, graft failure, delayed immune reconstitution, and high incidence of viral infection are still major problems. 8 We present a patient who developed graft rejection due to HPS after initial CBT and who underwent a second CBT following reduced-intensity conditioning.
A 54-year-old Japanese man developed AML (FAB: M4) in October 2005 and received induction chemotherapy consisting of idarubicin and Ara-C but failed to achieve CR. Then, he received high-dose Ara-C chemotherapy but he could not achieve remission. There were no available HLA-identical donors. Owing to refractory disease, he underwent CBT after myeloablative conditioning consisting of TBI of 12 Gy in six fractions from days À8 to À6, Ara-C 2 g m À2 twice daily i.v. on days À5 and À4 (total dose 8 g m
À2
) and CY 60 mg kg À1 once daily i.v. on days À3 and À2 (total dose 120 mg kg À1 ). He received an infusion of serologically one-antigen mismatched unrelated cord blood containing 2.7 Â 10 7 nucleated cells kg À1 (Table 1) . CsA and short-term MTX were administered for prophylaxis against GVHD. G-CSF was administered from day 1. Primary engraftment with neutrophils 4500 ml À1 was achieved on day 27, but he developed fever, polyarthralgia and general eruption on day 30. BM examination on day 33 revealed hypocellular marrow with 20% macrophages and severe hemophagocytosis. Chimerism analysis of BM MNC revealed 100% donor cells. Serum ferritin was elevated at 29 210 ng ml À1 and the patient was diagnosed with HPS. Prednisolone (PSL) 2 mg kg À1 was started with improvement of his symptoms, but G-CSF was necessary because of progressive pancytopenia. As CMV antigenemia became positive on day 39, foscarnet was started and PSL was tapered. The antigenemia and PCR test for CMV in peripheral blood became negative. However, pancytopenia progressed, with his WBC count being 100 ml À1 on day 57, and it did not respond to an increase in PSL dose to 2 mg kg
À1
. BM examination on day 65 revealed severe hypocellular marrow without donor cells by chimerism analysis and graft rejection was diagnosed. Following conditioning with fludarabine 30 mg m À2 from days À5 to À2, a second CBT was performed on day 77 from the initial CBT with infusion of serologically two loci-mismatched unrelated cord blood containing 3.7 Â 10 7 nucleated cells kg À1 . CsA was continued for GVHD prophylaxis. At the time of conditioning, serum ferritin was 3998 ng ml
. On day 13 post-second CBT, he developed fever, polyarthralgia, and eruption again and serum ferritin was increased at 34 020 ng ml
. Methylprednisolone 500 mg per day was given for 3 days with resolution of his symptoms and decrease in ferritin level. On day 18, engraftment was achieved with neutrophil count4500 ml
. Complete donor chimerism was confirmed on day 29. After the engraftment, CMV antigenemia became repeatedly positive but was successfully controlled with foscarnet treatment. Serum ferritin remained above 5000 ng ml À1 for 3 months postsecond CBT, but the patient did not develop clinically active HPS. The patient remains in CR and in good health 1 year after the second CBT without developing GVHD. HPS is characterized by proliferation and organ infiltration of activated macrophages under conditions such as infection, lymphoma, and autoimmune disease. 9 Some HPS cases are fatal. There are several reports of early-onset HPS after SCT. [2] [3] [4] [5] Both donor-and recipient-derived macrophages can cause HPS after allo-SCT. In our patient, chimerism analysis of BM MNC at the onset of HPS revealed 100% donor cells, indicating that the proliferating activated macrophages were donor-derived.
The underlying cause of HPS after allo-SCT is heterogeneous and CMV infection may cause HPS after allo-SCT. 10 Our patient developed HPS before CMV antigenemia became positive. Therefore, the main cause of HPS in our patient was thought to be an unknown immune mechanism but CMV infection, which may have been exacerbated by the steroids given for the treatment of HPS, might also have caused significant damage on graft function.
The guidelines for second SCT by Wolff 1 recommend that if immunologic mechanisms of graft dysfunction are expected, the second infusion should be accompanied by additional immuno-suppression therapy. Graft rejection due to HPS is a fatal condition and the only way to save the patient is to perform a second SCT. However, second SCT for graft rejection due to HPS has not been established. Tanaka et al.
2 reported a case of second haploidentical PBSCT for graft rejection after CBT by HPS. Because our patient had no donor candidate, we selected cord blood as the stem cell source. Because activated donor-derived macrophages were not observed in the BM when graft rejection was diagnosed and considering the patients poor general condition, we selected fludarabine as the reducedintensity conditioning regimen for the second CBT without additional anti-cancer drugs such as VP-16. Although the serum ferritin was elevated before engraftment, the patient was successfully engrafted and has sustained good graft function without developing active HPS after the engraftment. This is the first report of successful second CBT following graft rejection by HPS after initial CBT. Because graft rejection with HPS is fatal, second CBT with reducedintensity conditioning regimen should be considered in appropriate timing if an alternative donor is not available. Chiba City, Japan E-mail: chiaki-nakaseko@faculty.chiba-u.jp
